alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EX-31 Rule13a-14(d)/15d-14(d) Certifications.

 

 

I, Kunal K. Singh,certify that:

 

1. I have reviewedthis report on Form 10-K and all reports on Form 10-D required to be filed inrespect of the period covered by this report on Form 10-K of the JPMBBCommercial Mortgage Securities Trust 2015-C31 (the "Exchange Act periodicreports");

 

2. Based on myknowledge, the Exchange Act periodic reports, taken as a whole, do not containany untrue statement of a material fact or omit to state a material fact necessaryto make the statements made, in light of the circumstances under which suchstatements were made, not misleading with respect to the period covered by thisreport;

 

3. Based on myknowledge, all of the distribution, servicing and other information required tobe provided under Form 10-D for the period covered by this report is includedin the Exchange Act periodic reports;

 

4. Based on myknowledge and the servicer compliance statements required in this report underItem 1123 of Regulation AB, and except as disclosed in the Exchange Actperiodic reports, the servicers have fulfilled their obligations under theservicing agreements in all material respects; and

 

5. All of the reportson assessment of compliance with servicing criteria for asset-backed securitiesand their related attestation reports on assessment of compliance withservicing criteria for asset-backed securities required to be included in thisreport in accordance with Item 1122 of Regulation AB and Exchange Act Rules13a-18 and 15d-18 have been included as an exhibit to this report, except asotherwise disclosed in this report. Any material instances of noncompliancedescribed in such reports have been disclosed in this report on Form 10-K.

 

In giving thecertifications above, I have reasonably relied on information provided to me bythe following unaffiliated parties:

 

Midland LoanServices, a Division of PNC Bank, National Association, as Master Servicer,Rialto Capital Advisors, LLC, as Special Servicer, Wells Fargo Bank, NationalAssociation, as Trustee and Certificate Administrator, Wells Fargo Bank,National Association, as Custodian, Pentalpha Surveillance LLC, as Senior TrustAdvisor, Wells Fargo Bank, National Association, as Primary Servicer for theBrunswick Portfolio Mortgage Loan, Torchlight Loan Services, LLC, as SpecialServicer for the Brunswick Portfolio Mortgage Loan, Wilmington Trust, NationalAssociation, as Trustee for the Brunswick Portfolio Mortgage Loan, Wells FargoBank, National Association, as Custodian for the Brunswick Portfolio MortgageLoan, Pentalpha Surveillance LLC, as Senior Trust Advisor for the BrunswickPortfolio Mortgage Loan, CoreLogic Commercial Real Estate Services, Inc., asServicing Function Participant for the Brunswick Portfolio Mortgage Loan, andNational Tax Search, LLC, as Servicing Function Participant for the BrunswickPortfolio Mortgage Loan.

 

 

 

Dated: March 20, 2020

 

 

/s/ Kunal K. Singh

 

 

President and ChiefExecutive Officer

(senior officerin charge of securitization of the depositor)
PFS CORPORATION 1 of 2 Created on: 2009-09-09 F95-8-5-CBScopeListingTemplate-2009-4-14 

## CERTIFICATION BODY ACCREDITATION PROGRAM

Accredited Legal Entity :



## PFS CORPORATION

1507 Matt Pass, Cottage Grove, WI 53527 U.S.A. Telephone: (608) 839-1013 Fax: (608) 839-1014 Email: jrothman@pfscorporation.com

Any additional critical/key locations included in the scope of accreditation are appended to this listing.

Accreditation Standards:

CAN-P-3G (ISO/IEC Guide 65:1996)
CAN-P-1500M
IAF GD 5:2006

Certification Mark:

Product Certification System Type:

The product certification system operated by this organization most closely resembles that described by ISO/IEC Guide 67, Conformity assessment — Fundamentals of product certification , System 5. It includes the evaluation of samples requested by the certification body, determination of characteristics by testing or assessment, initial assessment of the production process or the quality system, as applicable, evaluation of the test and assessment reports, license, on-going surveillance by testing or inspection of samples from the factory or the open market, or both depending on the product type, as well as on-going surveillance of the production process or quality system or both.

Subject Areas of Accreditation:

The scope of accreditation for the above-mentioned legal entity limits the use of the certification mark shown, to products that meet standards classified by the following international classification coding:PFS CORPORATION 2 of 2 Created on: 2009-09-09 F95-8-5-CBScopeListingTemplate-2009-4-14

ICS No. Title Purpose 13.220.40 Ignitability and burning behaviour of materials and products Safety & Performance 13.220.50 Fire-resistance of building materials and elements Performance 79.040 Wood, sawlogs and sawn timber Performance 79.060.01 Wood–based panels in General Performance 79.060.10 Plywood Performance 79.060.20 Fibre and particle boards Performance

79.080 Semi-manufactures of timber Performance 83.080.20 Thermoplastic Materials Performance 91.060.10 Walls. Partitions. Façades Performance

91.060.20 Roofs Performance 91.060.30 Ceilings. Floors. Stairs Performance

91.080.20 Timber structures Performance 91.100.99 Other construction materials (Construction adhesives for wood) Performance

91.140.10 Central heating systems (Gas, oil and solid fuel-fired systems only) Performance and Safety

97.040.20 Cooking ranges, working tables, ovens and similar appliances Performance and Gas Safety

97.100.20 Gas heaters Performance Gas Safety Energy Efficiency 97.100.30 Solid fuel heaters Performance and Safety 97.100.40 Liquid fuel heaters Performance and Safety 97.180 Miscellaneous domestic and commercial equipment (Campsite fire logs, starts, and gas-fired log lighters) Performance and Safety

Other Critical/Key Locations

The certification activities conducted by the above-mentioned legal entity at the following locations are also included in this scope of accreditation:

Country Address Location United States PFS Corporation 3637 Motor Ave., Suite 380 Los Angeles, CA 90034 Los Angeles
<PAGE>

                                                                    EXHIBIT 99.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Home Products International, Inc.
(the "Company") on Form 10-Q for the period ended March 29, 2003 as filed with
the Securities and Exchange Commission on May 12, 2003, I, James R. Tennant,
Chief Executive Officer and Chairman of the Board of the Company, certify,
pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the
Sarbanes-Oxley Act of 2002, that:

(1)  The Report fully complies with the requirements of section 13(a) or 15(d)
     of the Securities Exchange Act of 1934; and

(2)  The information contained in the Report fairly presents, in all material
     respects, the financial condition and results of operations of the Company.

/s/ JAMES R. TENNANT
James R. Tennant
Chief Executive Officer and Chairman of the Board
May 12, 2003

A signed original of this written statement required by Section 906 has been
provided to Home Products International, Inc. and will be retained by Home
Products International, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request.
<PAGE>
                                                                   EXHIBIT 10.29

                               FIRST AMENDMENT TO

                          M/I SCHOTTENSTEIN HOMES, INC.

                     EXECUTIVES' DEFERRED COMPENSATION PLAN


WHEREAS, effective January 1, 2001, M/I Schottenstein Homes, Inc. ("Company")
adopted an amended and restated version of the M/I Schottenstein Homes, Inc.
Executives' Deferred Compensation Plan ("Plan") to provide its Executives with
an opportunity to defer all or a portion of their Eligible Compensation and to
invest in the Company's Common Shares; and

WHEREAS, the Company also retained in Section 10 of the Plan the right to amend
the Plan at any time;

NOW, THEREFORE, effective July 1, 2001:

     1.   Plan Section 5.A is amended to read in its entirety, as follows:

               A. Time of Payment. Distribution of a Participant's Deferred
          Compensation Account for a specific Plan Year shall be made on or
          about the 50th day, but in no event later than the 60th day, after the
          earlier of (i) the date specified by the Participant in the Deferral
          Notice delivered to the Plan Administrator or in any properly
          delivered Amendment to Deferral Notice; or (ii) the Participant's
          Termination Date.


     2.   The Deferral Notice attached to the Plan as an exhibit shall be
          replaced by the Deferral Notice attached to this Amendment.

          IN WITNESS WHEREOF, the Company has caused this Amendment to be
     executed by a duly authorized officer.


                                             M/I SCHOTTENSTEIN HOMES, INC.



                                             By:________________________________


                                             Its:_______________________________
                                                       Name (Please Print)
March 22 , 20 12



### JUDGMENT 

## The Fourteenth Court of Appeals

CHRISTOPHER MOUTON , Appellant

NO. 14

- 11

- 00 295

- CR V.

THE STATE OF TEXAS , Appellee

____________________

This cause was heard on the record of the court below. Having considered th e record , this Court holds that there was no error in the judgment. The Court orders the judgment AFFIRMED, that t he appellant pay all costs expended in this appeal, and that
this decision be certified below for observance.
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.1325 Electroglottograph. ( a ) *Identification.* An electroglottograph is an AC-powered device that employs a pair of electrodes that are placed in contact with the skin on both sides of the larynx and held in place by a collar. It is intended to measure the electrical impedance of the larynx to aid in assessing the degree of closure of the vocal cords, confirm larygeal diagnosis, aid behavioral treatment of voice disorders, and aid research concerning the laryngeal mechanism.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 874.9.
[51 FR 40389, Nov. 6, 1986, as amended at 84 FR 71813, Dec. 30, 2019]
# C_2015127EN.01002902.xml

| 20.4.2015 | EN | Official Journal of the European Union | C 127/29 |
| --- | --- | --- | --- |

20.4.2015

EN

Official Journal of the European Union

C 127/29

---

Action brought on 28 November 2014 — Staatliche Porzellan-Manufaktur Meissen v OHIM — Meissen Keramik (MEISSEN)

(Case T-789/14)

(2015/C 127/41)

Language in which the application was lodged: German

Parties

Parties

Applicant: Staatliche Porzellan-Manufaktur Meissen GmbH (Meißen, Germany) (represented by: O. Spuhler and M. Geitz, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM)

Defendant:

Other party to the proceedings before the Board of Appeal: Meissen Keramik GmbH (Meißen, Germany)

Other party to the proceedings before the Board of Appeal:

Details of the proceedings before OHIM

Details of the proceedings before OHIM

Applicant for the trade mark at issue: Other party to the proceedings before the Board of Appeal

Applicant for the trade mark at issue:

Trade mark at issue: Community figurative mark containing the word element ‘MEISSEN’ — Application No 9 413 527

Trade mark at issue:

Procedure before OHIM: Opposition proceedings

Procedure before OHIM

Contested decision: Decision of the Fourth Board of Appeal of OHIM of 29 September 2014 in Cases R 1182/2013-4 and R 1245/2013-4

Contested decision

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | order the defendant to pay the costs. |
| --- | --- |

—

order the defendant to pay the costs.

Pleas in law

Pleas in law

| — | Infringement of Article 8(5) of Regulation No 207/2009; |
| --- | --- |

—

Infringement of Article 8(5) of Regulation No 207/2009;

| — | Infringement of Article 8(1)(b) of Regulation No 207/2009; |
| --- | --- |

—

Infringement of Article 8(1)(b) of Regulation No 207/2009;

| — | Infringement of Article 8(1)(b) of Regulation No 207/2009; |
| --- | --- |

—

Infringement of Article 8(1)(b) of Regulation No 207/2009;

| — | Infringement of Article 8(1)(b) of Regulation No 207/2009; |
| --- | --- |

—

Infringement of Article 8(1)(b) of Regulation No 207/2009;

| — | Infringement of Article 8(1)(b) of Regulation No 207/2009; |
| --- | --- |

—

Infringement of Article 8(1)(b) of Regulation No 207/2009;

| — | Infringement of Article 15(1) of Regulation No 207/2009. |
| --- | --- |

—

Infringement of Article 15(1) of Regulation No 207/2009.

---
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1875 Stethoscope. ( a ) *Manual stethoscope* — ( 1 ) *Identification.* A manual stethoscope is a mechanical device used to project the sounds associated with the heart, arteries, and veins and other internal organs.
( 2 ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.
( b ) *Electronic stethoscope* — ( 1 ) *Identification.* An electronic stethoscope is an electrically amplified device used to project the sounds associated with the heart, arteries, and veins and other internal organs.
( 2 ) *Classification.* Class II (special controls). The device, when it is a lung sound monitor, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.
[45 FR 7907, Feb. 5, 1980, as amended at 59 FR 63007, Dec. 7, 1994; 66 FR 38796, July 25, 2001; 84 FR 71811, Dec. 30, 2019]
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.4075 Endomyocardial biopsy device. ( a ) *Identification.* An endomyocardial biopsy device is a device used in a catheterization procedure to remove samples of tissue from the inner wall of the heart.
( b ) *Classification.* Class II (performance standards).
§ 99.305 Exemption from the requirement to file a supplemental application. ( a ) Within 60 days after receipt of an application for an exemption from the requirement of a supplemental application, FDA shall approve or deny the application. ( 1 ) If FDA does not act on the application for an exemption within the 60-day period, the application for an exemption shall be deemed to be approved.
( 2 ) If an application for an exemption is deemed to be approved, FDA may, at any time, terminate such approval if it determines that the requirements for granting an exemption have not been met. FDA shall notify the manufacturer if the approval is terminated.
( b ) In reviewing an application for an exemption, FDA shall consider the materials submitted by the manufacturer and may consider any other appropriate information, including, but not limited to, any pending or previously approved applications for exemption submitted by the manufacturer.
( c ) FDA may grant an application for an exemption if FDA determines that: ( 1 ) It would be economically prohibitive for the manufacturer to incur the costs necessary to submit a supplemental application for a new use, which at a minimum requires: ( i ) That existing data characterizing the safety and effectiveness of the drug or device, including data from the study described in the information to be disseminated are not adequate to support the submission of a supplemental application for the new use; and
( ii ) That the cost of the study or studies for the new use reasonably exceeds the expected revenue from the new use minus the cost of goods sold and marketing and administrative expenses attributable to the new use of the product, and there are not less expensive ways to obtain the needed information; or
( 2 ) It would be unethical to conduct clinical studies needed to support the submission of a supplemental application for the new use because: ( i ) Existing data characterizing the safety and effectiveness of the drug or device, including data from the study described in the information to be disseminated are not adequate to support the submission of a supplemental application for the new use; and
( ii ) Although available evidence would not support the submission of a supplemental application for the new use, the data are persuasive to the extent that withholding the drug or device in a controlled study would pose an unreasonable risk of harm to human subjects and no studies in different populations or of modified design can be utilized. In determining whether it would be unethical to conduct clinical studies, the agency shall consider, in addition to the persuasiveness of available evidence of effectiveness, whether the new use of the drug or device is broadly accepted as current standard medical treatment or therapy.
* Pursuant to 5 TH C IR . R. 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 00-51012 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus BENITO RODRIGUEZ-ORTIZ, Defendant-Appellant.

-------------------- Appeal from the United States District Court for the Western District of Texas USDC No. A-00-CR-72-ALL-JN

-------------------- April 12, 2001 Before JOLLY, HIGGINBOTHAM, and JONES, Circuit Judges. PER CURIAM: * Enrique Rodriguez-Ortiz appeals the 70-month sentence imposed following his plea of guilty to a charge of being found in the United States after deportation, a violation of 8 U.S.C. § 1326. For the first time on appeal, Rodriguez argues that the aggravated-felony conviction that resulted in his increased sentence under 8 U.S.C. § 1326(b)(2) was an element of the offense that should have been charged in the information to which he pleaded guilty.No. 00-51012 -2- Rodriguez acknowledges that his argument is foreclosed by the Supreme Court’s decision in Almendarez-Torres v. United States , 523 U.S. 224 (1998), but he seeks to preserve the issue for Supreme Court review in light of the decision in Apprendi v. New Jersey , 120 S. Ct. 2348 (2000). Apprendi did not overrule Almendarez-Torres
. See Apprendi , 120 S. Ct. at 2362; United States v. Dabeit , 231 F.3d 979, 984 (5th Cir. 2000), cert. denied , 121 S. Ct. 1214 (2001). Rodriguez has failed to demonstrate error, plain or otherwise. Dabeit , 231 F.3d at 983-84. The judgment of the district court is
AFFIRMED.
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology. ( a ) *Identification.* ( 1 ) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.
( 2 ) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
( b ) *Classification.* ( 1 ) Class II.
( 2 ) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
[53 FR 23872, June 24, 1988, as amended at 61 FR 1123, Jan. 16, 1996; 66 FR 38803, July 25, 2001]
From: Sagar Chitre
To: Goehl, Eric Cc: George Salinas Subject: RE: BTB Refining, LLC-Area Source of HAPS
Date: Wednesday, September 18, 2013 4:52:30 PM

Dear Mr. Goehl,

As per our telephonic conversation today afternoon, I wish to confirm that BTB Refining, L.L.C. is not a major source of Hazardous Air Pollutants (HAP). BTB Refining, L.L.C. is an area source of HAP.

If you need more information or have any questions in this regard, please feel free to contact me at (361) 939-5128.

Sincerely, Sagar Chitre Environmental Specialist BTB Refining, L.L.C.
<PAGE>

                                  EXHIBIT 10(b)

                      REVOLVING LOAN AND SECURITY AGREEMENT
                  CONVERTIBLE REVOLVING CREDIT PROMISSORY NOTE
                             DATED OCTOBER 26, 1987



                                  HOWTEK, INC.
                                 21 PARK AVENUE
                                HUDSON, NH 03051


                                                                   June 28, 2002

Mr. Robert H. Howard
303 East 57th Street
New York, NY 10022

      Re:  Revolving Loan and Security Agreement dated October 26, 1987 between
      Robert Howard and Howtek, Inc. ("Howtek") and the related Convertible
      Revolving Credit Promissory Note, as amended (the "Note"), made by
      Howtek in favor of Robert Howard

Dear Mr. Howard:

      This letter ("Amendment") hereby amends the Note as follows:

      1. The first sentence of the first paragraph of Paragraph I of the Note
is hereby amended and restated in its entirety as follows:

      "The Holder hereof shall have the right, at the Holder's option, at any
time from and after April 6, 1988 to and including the date on which the
principal amount of and interest on this Note is paid in full, subject to the
terms and provisions hereof, to convert all or any part of the Outstanding
Principal Amount of this Note and any accrued but unpaid interest thereunder
into fully paid and nonassessable shares of the common stock, par value $.01 per
share, of the Borrower (the "Stock") (as such shares shall be constituted at the
time of conversion) at the conversion price equal to the lesser of (i) the
closing sale price of the Stock on the date that such principal amount of this
Note being converted was advanced hereunder or (ii) the closing sale price of
the Stock on the last business day immediately preceding the date of conversion
(the "Conversion Price").

      2. The Maturity Date set forth in Paragraph D of the Note is hereby
extended from January 4, 2003 to January 4, 2004.

      3. Except as modified by this Amendment, the Note shall continue
unmodified and in full force and effect.

<PAGE>

               Please sign this Amendment at the place indicated below,
whereupon it shall constitute our mutually binding agreement with respect to the
matters contained herein.


                                                       Very truly yours,



                                                       HOWTEK, INC.


                                                       By: /s/ W. Scott Parr
                                                         -----------------------
                                                       Name:   W. Scott Parr
                                                       Title:  President & CEO


AGREED TO AND ACCEPTED BY:

/s/  Robert Howard
----------------------
  Robert Howard